Novartis Foundation and partners launch initiative to tackle hypertension and its root causes in low-income urban communities
- Details
- Category: Novartis
On World Hypertension Day 2017, the Novartis Foundation and its partners, including Intel Corporation, the NCD Alliance, city governments and local partners, announce the launch of Better Hearts Better Cities, an innovative initiative to address the high rates of high blood pressure (hypertension) in low-income urban communities.
Boehringer Ingelheim inaugurates world-class biopharmaceutical manufacturing facility in China
- Details
- Category: Boehringer Ingelheim
Today, Boehringer Ingelheim inaugurated its commercial production site for biopharmaceuticals in Zhang Jiang Hi-tech Park of Shanghai (China). The site, with the first-phase investment of more than €70 million, is the first and only biopharmaceutical facility established by a leading multinational active biopharmaceutical manufacturer in China utilizing mammalian cell culture technology.
Imfinzi significantly reduces the risk of disease worsening or death in the Phase III PACIFIC trial for Stage III unresectable lung cancer
- Details
- Category: AstraZeneca
AstraZeneca and MedImmune, its global biologics research and development arm, today announced positive results for the Phase III PACIFIC trial, a randomised, double-blinded, placebo-controlled multi-centre trial of Imfinzi (durvalumab) as sequential treatment in patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer (NSCLC) who had not progressed following standard platinum-based chemotherapy concurrent with radiation therapy.
Sangamo Therapeutics and Pfizer announce collaboration for Hemophilia A gene therapy
- Details
- Category: Pfizer
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and Pfizer Inc. (NYSE: PFE) have announced an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Hemophilia A, including SB-525, one of Sangamo's four lead product candidates, which Sangamo expects will enter the clinic this quarter.
SERMO unveils first global physician-to-physician drug ratings tool
- Details
- Category: Business
SERMO, the largest global social network for physicians with 650,000 members worldwide, has announced the groundbreaking new "Drug Ratings" tool. Drug Ratings is the first and only global peer-to-peer prescription drug review system sourced exclusively from verified licensed physicians. With more than a quarter million ratings and 20,000 comments from doctors worldwide to date in the beta release, the Ratings platform is quickly becoming the largest global database of physician feedback on drugs.
Merck acquires Grzybowski Scientific Inventions to expand chemical synthesis offering
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced the acquisition of Grzybowski Scientific Inventions (GSI), a company that developed the revolutionary computer-aided retro-synthesis tool, Chematica. Chematica uses advanced reaction rules and proprietary algorithms to identify synthesis pathways that meet user-defined constraints.
Abbott announces CE Mark and first use of the world's first smartphone compatible insertable cardiac monitor
- Details
- Category: Abbott
Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm RxTM Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will help physicians identify difficult to detect cardiac arrhythmias, including atrial fibrillation (AF), to help guide therapy. Since CE Mark approval, adoption of the device has been strong and implants have occurred in 10 countries across Europe.
More Pharma News ...
- Novartis exercises exclusive option agreement with Conatus for the treatment of NASH
- Grants4Apps Accelerator and new Dealmaker now open for submissions
- AstraZeneca marks a key milestone with the ‘topping out’ of new global R&D centre and HQ in Cambridge, UK
- New data at AAN reinforce clinical benefit of Roche's OCREVUS™ (ocrelizumab) for relapsing and primary progressive multiple sclerosis
- Merck divests Biosimilars business to Fresenius
- Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS
- Pfizer unveils ATLAS®, an interactive, user-friendly website that provides global antibiotic resistance surveillance data across 60 countries